Cargando…
Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques
Viruses are increasingly used as vectors for delivery of genetic material for gene therapy and vaccine applications. Recombinant adeno-associated viruses (rAAVs) are a class of viral vector that is being investigated intensively in the development of gene therapies. To develop efficient rAAV therapi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074050/ https://www.ncbi.nlm.nih.gov/pubmed/33923984 http://dx.doi.org/10.3390/pharmaceutics13040586 |
_version_ | 1783684268128468992 |
---|---|
author | Cole, Liam Fernandes, Diogo Hussain, Maryam T. Kaszuba, Michael Stenson, John Markova, Natalia |
author_facet | Cole, Liam Fernandes, Diogo Hussain, Maryam T. Kaszuba, Michael Stenson, John Markova, Natalia |
author_sort | Cole, Liam |
collection | PubMed |
description | Viruses are increasingly used as vectors for delivery of genetic material for gene therapy and vaccine applications. Recombinant adeno-associated viruses (rAAVs) are a class of viral vector that is being investigated intensively in the development of gene therapies. To develop efficient rAAV therapies produced through controlled and economical manufacturing processes, multiple challenges need to be addressed starting from viral capsid design through identification of optimal process and formulation conditions to comprehensive quality control. Addressing these challenges requires fit-for-purpose analytics for extensive characterization of rAAV samples including measurements of capsid or particle titer, percentage of full rAAV particles, particle size, aggregate formation, thermal stability, genome release, and capsid charge, all of which may impact critical quality attributes of the final product. Importantly, there is a need for rapid analytical solutions not relying on the use of dedicated reagents and costly reference standards. In this study, we evaluate the capabilities of dynamic light scattering, multiangle dynamic light scattering, and SEC–MALS for analyses of rAAV5 samples in a broad range of viral concentrations (titers) at different levels of genome loading, sample heterogeneity, and sample conditions. The study shows that DLS and MADLS(®) can be used to determine the size of full and empty rAAV5 (27 ± 0.3 and 33 ± 0.4 nm, respectively). A linear range for rAAV5 size and titer determination with MADLS was established to be 4.4 × 10(11)–8.7 × 10(13) cp/mL for the nominally full rAAV5 samples and 3.4 × 10(11)–7 × 10(13) cp/mL for the nominally empty rAAV5 samples with 3–8% and 10–37% CV for the full and empty rAAV5 samples, respectively. The structural stability and viral load release were also inferred from a combination of DLS, SEC–MALS, and DSC. The structural characteristics of the rAAV5 start to change from 40 °C onward, with increasing aggregation observed. With this study, we explored and demonstrated the applicability and value of orthogonal and complementary label-free technologies for enhanced serotype-independent characterization of key properties and stability profiles of rAAV5 samples. |
format | Online Article Text |
id | pubmed-8074050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80740502021-04-27 Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques Cole, Liam Fernandes, Diogo Hussain, Maryam T. Kaszuba, Michael Stenson, John Markova, Natalia Pharmaceutics Article Viruses are increasingly used as vectors for delivery of genetic material for gene therapy and vaccine applications. Recombinant adeno-associated viruses (rAAVs) are a class of viral vector that is being investigated intensively in the development of gene therapies. To develop efficient rAAV therapies produced through controlled and economical manufacturing processes, multiple challenges need to be addressed starting from viral capsid design through identification of optimal process and formulation conditions to comprehensive quality control. Addressing these challenges requires fit-for-purpose analytics for extensive characterization of rAAV samples including measurements of capsid or particle titer, percentage of full rAAV particles, particle size, aggregate formation, thermal stability, genome release, and capsid charge, all of which may impact critical quality attributes of the final product. Importantly, there is a need for rapid analytical solutions not relying on the use of dedicated reagents and costly reference standards. In this study, we evaluate the capabilities of dynamic light scattering, multiangle dynamic light scattering, and SEC–MALS for analyses of rAAV5 samples in a broad range of viral concentrations (titers) at different levels of genome loading, sample heterogeneity, and sample conditions. The study shows that DLS and MADLS(®) can be used to determine the size of full and empty rAAV5 (27 ± 0.3 and 33 ± 0.4 nm, respectively). A linear range for rAAV5 size and titer determination with MADLS was established to be 4.4 × 10(11)–8.7 × 10(13) cp/mL for the nominally full rAAV5 samples and 3.4 × 10(11)–7 × 10(13) cp/mL for the nominally empty rAAV5 samples with 3–8% and 10–37% CV for the full and empty rAAV5 samples, respectively. The structural stability and viral load release were also inferred from a combination of DLS, SEC–MALS, and DSC. The structural characteristics of the rAAV5 start to change from 40 °C onward, with increasing aggregation observed. With this study, we explored and demonstrated the applicability and value of orthogonal and complementary label-free technologies for enhanced serotype-independent characterization of key properties and stability profiles of rAAV5 samples. MDPI 2021-04-20 /pmc/articles/PMC8074050/ /pubmed/33923984 http://dx.doi.org/10.3390/pharmaceutics13040586 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cole, Liam Fernandes, Diogo Hussain, Maryam T. Kaszuba, Michael Stenson, John Markova, Natalia Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques |
title | Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques |
title_full | Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques |
title_fullStr | Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques |
title_full_unstemmed | Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques |
title_short | Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques |
title_sort | characterization of recombinant adeno-associated viruses (raavs) for gene therapy using orthogonal techniques |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074050/ https://www.ncbi.nlm.nih.gov/pubmed/33923984 http://dx.doi.org/10.3390/pharmaceutics13040586 |
work_keys_str_mv | AT coleliam characterizationofrecombinantadenoassociatedvirusesraavsforgenetherapyusingorthogonaltechniques AT fernandesdiogo characterizationofrecombinantadenoassociatedvirusesraavsforgenetherapyusingorthogonaltechniques AT hussainmaryamt characterizationofrecombinantadenoassociatedvirusesraavsforgenetherapyusingorthogonaltechniques AT kaszubamichael characterizationofrecombinantadenoassociatedvirusesraavsforgenetherapyusingorthogonaltechniques AT stensonjohn characterizationofrecombinantadenoassociatedvirusesraavsforgenetherapyusingorthogonaltechniques AT markovanatalia characterizationofrecombinantadenoassociatedvirusesraavsforgenetherapyusingorthogonaltechniques |